Plant-derived antigens as mucosal vaccines

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

During the last two decades, researchers have developed robust systems for recombinant subunit vaccine production in plants. Stably and transiently transformed plants have particular advantages that enable immunization of humans and animals via mucosal delivery. The initial goal to immunize orally by ingestion of plant-derived antigens has proven difficult to attain, although many studies have demonstrated antibody production in both humans and animals, and in a few cases, protection against pathogen challenge. Substantial hurdles for this strategy are low-antigen content in crudely processed plant material and limited antigen stability in the gut. An alternative is intranasal delivery of purified plant-derived antigens expressed with robust viral vectors, especially virus-like particles. The use of pattern recognition receptor agonists as adjuvants for mucosal delivery of plant-derived antigens can substantially enhance serum and mucosal antibody responses. In this chapter, we briefly review the methods for recombinant protein expression in plants, and describe progress with human and animal vaccines that use mucosal delivery routes. We do not attempt to compile a comprehensive list, but focus on studies that progressed to clinical trials or those that showed strong indications of efficacy in animals. Finally, we discuss some regulatory concerns regarding plant-based vaccines.

Original languageEnglish (US)
Pages (from-to)101-120
Number of pages20
JournalCurrent Topics in Microbiology and Immunology
Volume354
Issue number1
DOIs
StatePublished - 2012

Fingerprint

Plant Antigens
Vaccines
Antibody Formation
Pattern Recognition Receptors
Antigens
Synthetic Vaccines
Subunit Vaccines
Recombinant Proteins
Virion
Immunization
Eating
Research Personnel
Clinical Trials
Serum

Keywords

  • Nasal immunization
  • Norovirus
  • Oral immunization
  • Plant viral vector
  • Toll-like receptor agonist

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology (medical)
  • Immunology
  • Microbiology

Cite this

Plant-derived antigens as mucosal vaccines. / Mason, H. S.; Herbst-Kralovetz, Melissa.

In: Current Topics in Microbiology and Immunology, Vol. 354, No. 1, 2012, p. 101-120.

Research output: Contribution to journalArticle

@article{7d0c7fd1d9e34ecdaa698c474a8fadb5,
title = "Plant-derived antigens as mucosal vaccines",
abstract = "During the last two decades, researchers have developed robust systems for recombinant subunit vaccine production in plants. Stably and transiently transformed plants have particular advantages that enable immunization of humans and animals via mucosal delivery. The initial goal to immunize orally by ingestion of plant-derived antigens has proven difficult to attain, although many studies have demonstrated antibody production in both humans and animals, and in a few cases, protection against pathogen challenge. Substantial hurdles for this strategy are low-antigen content in crudely processed plant material and limited antigen stability in the gut. An alternative is intranasal delivery of purified plant-derived antigens expressed with robust viral vectors, especially virus-like particles. The use of pattern recognition receptor agonists as adjuvants for mucosal delivery of plant-derived antigens can substantially enhance serum and mucosal antibody responses. In this chapter, we briefly review the methods for recombinant protein expression in plants, and describe progress with human and animal vaccines that use mucosal delivery routes. We do not attempt to compile a comprehensive list, but focus on studies that progressed to clinical trials or those that showed strong indications of efficacy in animals. Finally, we discuss some regulatory concerns regarding plant-based vaccines.",
keywords = "Nasal immunization, Norovirus, Oral immunization, Plant viral vector, Toll-like receptor agonist",
author = "Mason, {H. S.} and Melissa Herbst-Kralovetz",
year = "2012",
doi = "10.1007/82_2011_158",
language = "English (US)",
volume = "354",
pages = "101--120",
journal = "Current Topics in Microbiology and Immunology",
issn = "0070-217X",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Plant-derived antigens as mucosal vaccines

AU - Mason, H. S.

AU - Herbst-Kralovetz, Melissa

PY - 2012

Y1 - 2012

N2 - During the last two decades, researchers have developed robust systems for recombinant subunit vaccine production in plants. Stably and transiently transformed plants have particular advantages that enable immunization of humans and animals via mucosal delivery. The initial goal to immunize orally by ingestion of plant-derived antigens has proven difficult to attain, although many studies have demonstrated antibody production in both humans and animals, and in a few cases, protection against pathogen challenge. Substantial hurdles for this strategy are low-antigen content in crudely processed plant material and limited antigen stability in the gut. An alternative is intranasal delivery of purified plant-derived antigens expressed with robust viral vectors, especially virus-like particles. The use of pattern recognition receptor agonists as adjuvants for mucosal delivery of plant-derived antigens can substantially enhance serum and mucosal antibody responses. In this chapter, we briefly review the methods for recombinant protein expression in plants, and describe progress with human and animal vaccines that use mucosal delivery routes. We do not attempt to compile a comprehensive list, but focus on studies that progressed to clinical trials or those that showed strong indications of efficacy in animals. Finally, we discuss some regulatory concerns regarding plant-based vaccines.

AB - During the last two decades, researchers have developed robust systems for recombinant subunit vaccine production in plants. Stably and transiently transformed plants have particular advantages that enable immunization of humans and animals via mucosal delivery. The initial goal to immunize orally by ingestion of plant-derived antigens has proven difficult to attain, although many studies have demonstrated antibody production in both humans and animals, and in a few cases, protection against pathogen challenge. Substantial hurdles for this strategy are low-antigen content in crudely processed plant material and limited antigen stability in the gut. An alternative is intranasal delivery of purified plant-derived antigens expressed with robust viral vectors, especially virus-like particles. The use of pattern recognition receptor agonists as adjuvants for mucosal delivery of plant-derived antigens can substantially enhance serum and mucosal antibody responses. In this chapter, we briefly review the methods for recombinant protein expression in plants, and describe progress with human and animal vaccines that use mucosal delivery routes. We do not attempt to compile a comprehensive list, but focus on studies that progressed to clinical trials or those that showed strong indications of efficacy in animals. Finally, we discuss some regulatory concerns regarding plant-based vaccines.

KW - Nasal immunization

KW - Norovirus

KW - Oral immunization

KW - Plant viral vector

KW - Toll-like receptor agonist

UR - http://www.scopus.com/inward/record.url?scp=84856148597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856148597&partnerID=8YFLogxK

U2 - 10.1007/82_2011_158

DO - 10.1007/82_2011_158

M3 - Article

C2 - 21811930

AN - SCOPUS:84856148597

VL - 354

SP - 101

EP - 120

JO - Current Topics in Microbiology and Immunology

JF - Current Topics in Microbiology and Immunology

SN - 0070-217X

IS - 1

ER -